**AbbVie Announces $195 Million Expansion of North Chicago Manufacturing Plant**
AbbVie has unveiled plans to invest $195 million in its North Chicago, Illinois manufacturing facility to boost domestic production of active pharmaceutical ingredients (APIs). The major expansion, slated to begin construction this fall, is a key part of the biopharmaceutical company’s broader strategy to invest over $10 billion in U.S.-based capital projects.
The new API facility will significantly enhance AbbVie’s chemical synthesis capabilities, supporting the production of both current and future medicines across neuroscience, immunology, and oncology disciplines. This development will strengthen the company’s existing footprint that already includes 11 manufacturing sites and supports more than 6,000 jobs nationwide.
“Over the next decade, AbbVie will expand production of API, drug product, peptides, and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, chairman and CEO of AbbVie. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
This investment reflects a continued commitment to domestic innovation and healthcare infrastructure, positioning AbbVie to play a leading role in the delivery of advanced medical therapies in the years ahead.
